Clinical Trial

Effectiveness of an eHealth Self-management Support Program for Persistent Pain After Breast Cancer Treatment

Study acronym: PECAN
Recruiting
View on ClinicalTrials.gov →
Summary
The scientific goals of the project are: 1. The primary scientific objective of the study is to determine the effectiveness of an eHealth self-management support program for persistent pain after breast cancer treatment compared to: * usual care (i.e. superiority of the eHealth self-management support program) and * a comprehensive pain rehabilitation program delivered face-to-face in a physical therapy setting (i.e. non-inferiority of the eHealth self-management support program) on pain-related disability (measured with the Pain Disability Index). 2. The secondary scientific objectives of this study entails to examine if the eHealth self-management support program has a relative benefit for other biopsychosocial factors, including: * Other dimensions of pain * Health-related quality of life * Physical functioning, including physical activity levels * Psychosocial functioning, including self-efficacy, stress, anxiety, depression, coping style (key secondary outcome) and fear of cancer recurrence * Participation in society, including return to work * Healthcare-related costs for the patient and society 3. The tertiary scientific objectives of this study are * to identify moderators of treatment effect, including behavioural determinants (e.g. self-efficacy, motivation, coping style), in order to identify breast cancer survivors who would benefit the most of the eHealth self-management support program and to allow more stratified and efficient pain management care and more targeted allocation of budgets. * To examine the implementation process, mechanisms of impact and contextual factors.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-03-06; most recent amendment 2025-06-20.
Status change: Not Yet Recruiting → Recruiting 2024-04-12
Trial Details
NCT Number NCT06308029
Lead Sponsor Universiteit Antwerpen
Collaborators: Universitaire Ziekenhuizen KU Leuven, University Ghent, KU Leuven, University Hospital, Antwerp
Conditions Breast Cancer
Enrollment 270 participants
Start Date 2024-05-26
Primary Completion 2028-06 (estimated)
Study Completion 2029-01 (estimated)
Updated on ClinicalTrials.gov 2025-06-26